EverImmune

Is developing the Oncobax® AK biotherapy, which uses immunogenic commensal bacteria to enhance the efficacy of immune checkpoint inhibitors. This approach is based on the modulation of intestinal microbiota to improve the response to immunotherapies in the treatment of kidney cancer and non-small cell lung cancer.